ExCEEd Orphan continues cooperation with Novartis Gene Therapies for Zolgensma®

ExCEEd Orphan will continue next year in cooperation with Novartis Gene Therapies (previously AveXis) in North Macedonia for Zolgensma®, the only approved gene therapy for spinal muscular atrophy (SMA).